AstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 2024 showcasing strength of its broad pipeline and portfolio

New data for TEZSPIRE and BREZTRI demonstrate AstraZeneca’s innovation and commitment to transform care in COPD

...

Related Keywords

China ,Japan ,San Diego ,California ,United States ,Brazil ,Brightling ,East Sussex ,United Kingdom ,Cambridge ,Cambridgeshire ,America ,American ,British ,Sharon Barr ,Lymphopoietin Isoforms ,Amgen ,American Lung Association ,International Conference ,Global Initiative On Obstructive Lung Disease ,Kyowa Kirin Co Ltd ,American Thoracic Society International Conference ,Astrazeneca ,Global Asthma Network ,Biowa Inc ,American Partnership For Eosinophilic Disorders ,National Heart ,Blood Institute ,Centers For Disease ,Global Initiative For Chronic Obstructive Lung Disease ,American Thoracic Society ,Executive Vice President ,Biopharmaceuticals Business Unit ,Bayesian Dynamic Borrowing Approach ,Albuterol Budesonide As Needed ,Janus Kinase ,British Early ,Not Exceed Recommended Dose ,Including Anaphylaxis ,Sympathomimetic Amines ,Certain Coexisting Conditions ,Adrenal Suppression ,Bone Mineral Density ,Prescribing Information ,Asthma Symptoms ,Patient Information ,Obstructive Pulmonary Disease ,Churg Strauss Syndrome ,North America ,Rare Diseases ,Global Initiative ,Chronic Obstructive Lung Disease ,Disease Control ,Leading Causes ,Accessed April ,Learn More Breathe Better ,Ultimate Relationship ,One Year Mortality ,Their Predictors ,Patients Hospitalized ,Nationwide Population Based ,First Year After Hospitalization ,Chronic Obstructive Pulmonary ,Obstructive Lung Disease ,Atherosclerosis Risk ,Eur Respir ,Global Asthma ,Global Asthma Report ,Eosinophilic Granulomatosis ,Zeneca Data ,Allergy Clin ,Zeneca Annual Report ,Very Severe Chronic Obstructive Pulmonary Disease ,Frequent Exacerbations ,Safety Study ,Patients With Hypereosinophilic Syndrome ,Stromal Lymphopoietin Isoforms ,Inflammatory Disorders ,Markets ,